A Diagnostics & Imaging Week

Lifeline Biotechnologies (Reno, Nevada) reported that it has begun preparation of a provisional patent on a new neural network diagnostic system after a five-year developmental period. As previously reported, Lifeline has been working with an unnamed Asian university to further develop and enhance the company's First Warning System. This pending patent is the result of that extensive work.

According to Dr. Louis Keith, emeritus professor of obstetrics and gynecology at the Northwestern University Feinberg School of Medicine (Chicago). "We can now determine which of the benign lesions the First Warning detects has the potential of becoming cancer. Using a combination of five neural network constructions, we have broken this elusive barrier. This new system has the ability to provide us with 100% selectivity, finding all lesions in the breast and with specificity in the low 90s, correctly classifying all tumors. This system will continue to improve in its accuracy because it learns with each new case presented to it."

Holmes added, "After our provisional patent is filed, we will begin a search for a strategic partner."

Lifeline Biotechnologies is focused on completing the development of the First Warning System, which is designed to assist in the early detection of breast cancer.